PRMT5 and metabolic dysfunction-associated steatotic liver disease: In light of our current findings, it will be important to consider that long‐term pharmacological inhibition of PRMT5 to treat cancer may cause severe side effects in liver, i.e. induce non‐alcoholic fatty liver disease.